Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax (NVAX) PT Raised to $38 at Ladenburg Thalmann
May 12, 2020 8:19 AM EDTLadenburg Thalmann analyst Michael Higgins raised the price target on Novavax (NASDAQ: NVAX) to $38.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "Last night, Novavax announced its 1Q20 results, presenting a $0.58 loss per share, better than our estimate of -$0.77... More
Epidemic response group to invest up to $384 mln in Novavax's COVID-19 vaccine
May 11, 2020 4:07 PM EDT(Reuters) - The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million to help develop and produce Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine candidate, the company said on Monday, sending its shares up 31.2% in extended trading.
CEPI, which was set up to fight emerging epidemics, said in March it would invest... More
Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine
May 11, 2020 4:06 PM EDTNovavax, Inc. (NASDAQ: NVAX) announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax coronavirus vaccine candidate against SARS-CoV-2. The additional funding from CEPI will also support rapid scale-up of the NVX-CoV2373 vaccine antigen, as well as Novavax proprietary Matrix-M adjuvant, which is expected to enhance immune responses by stimulating high levels of neutralizing antibodies. In addition, the CEPI funding will allow Novavax to dramatically increase its large-scale manufacturing capacity for both antigen and... More
Novavax (NVAX) to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
May 11, 2020 11:53 AM EDTNovavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax coronavirus vaccine candidate, on Wednesday, May 13, 2020 as part of the World... More
